

Board Update

Memphasys Limited (ASX: MEM), a biotechnology company focused on the development and commercialisation of innovative assisted reproduction technologies, announces the resignation of Mr Michael Atkins as Non-Executive Director of the Company.

Mr Atkins joined the Board in March 2024, bringing with him extensive experience in capital markets and corporate governance across numerous ASX-listed companies. During his tenure, Michael provided valuable strategic insight and guidance to both the Board and executive team as Memphasys continued to progress its commercialisation of the Felix™ System and advancement of key projects in assisted reproduction.

Mr Atkins is stepping down due to competing time commitments, and the Board extends its sincere thanks for his contribution and wishes him continued success in his other directorships.

The Board remains well-positioned to support the Company's growth strategy, with the recent appointment of Mr Marjan Mikel adding further depth in commercialisation, global market development, and the reproductive health sector. Mr Mikel's skill set ensures that the Board retains strong commercial capability and sector expertise following Mr Atkins' departure.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Dr. David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys Limited

Memphasys Limited (ASX: MEM) specialises in advanced reproductive biotechnology, developing medical devices, diagnostics, and proprietary media for human and animal applications. With flagship technologies like the Felix™ and RoXsta™ Systems, Memphasys is committed to delivering transformative solutions that enhance fertility outcomes worldwide.

Website: www.memphasys.com